博瑞医药：BGM0504片获批在成人超重/肥胖患者中开展临床试验

Core Viewpoint - 博瑞医药's subsidiary, 博瑞制药, has received approval from the National Medical Products Administration for clinical trials of BGM0504 tablets in overweight/obese adults, highlighting the company's advancements in metabolic disease treatments [1] Group 1: Product Development - BGM0504 is a dual agonist of GLP-1 and GIP receptors, designed to control blood sugar, promote weight loss, and treat non-alcoholic fatty liver disease (NASH) [1] - The injectable form of BGM0504 is currently in Phase III clinical trials for type 2 diabetes and weight loss indications in China [1] - BGM0504 tablets represent an oral formulation of BGM0504, with no similar oral formulations approved globally to date [1]